Transforming Transplants, Empowering Lives
At Geistek Pharmaceuticals, we understand the critical importance of transplant immunology in the field of organ transplantation. Our mission is to bridge the gap between transplant medicine and immunology, paving the way for successful and long-lasting organ transplants.
Transplantation is a life-saving procedure that restores hope and improves the quality of life for patients in need of organ replacement. However, the success of organ transplantation relies heavily on understanding and managing the complex interplay between the immune system and transplanted organs.
With our deep expertise in transplant immunology, we are dedicated to advancing the field through cutting-edge research, innovative therapies, and specialized care. Our multidisciplinary team of experts collaborates closely with transplant surgeons, immunologists, and other healthcare professionals to develop personalized treatment strategies tailored to each patient’s unique immunological profile.
Geistek Pharmaceuticals is at the forefront of transplant immunology research, exploring new approaches to prevent organ rejection, improve graft survival, and enhance patient outcomes. Through our comprehensive clinical trials and studies, we strive to identify novel immunomodulatory therapies and precision medicine solutions that optimize transplant outcomes.
We are committed to addressing the challenges faced by transplant recipients, including the risk of rejection, complications, and long-term immunosuppression. By leveraging the latest advancements in immunological understanding, we aim to develop innovative therapies that strike a balance between preventing rejection and minimizing the side effects of immunosuppressive drugs.
Geistek Pharmaceuticals also recognizes the importance of patient education and support throughout the transplant journey. We provide resources and guidance to patients and their families, empowering them with knowledge and understanding to make informed decisions and actively participate in their care.
Our dedication to regulatory compliance, ethical standards, and patient safety is paramount in everything we do. We collaborate closely with regulatory authorities, transplant centers, and healthcare organizations to ensure the highest quality standards and adherence to best practices in transplant immunology.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
